Divalproex Sodium Market Report 2026

The divalproex sodium market size has grown strongly in recent years. It will grow from $1.96 billion in 2025 to $2.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to high prevalence of epilepsy, long-standing clinical usage, limited alternative therapies, physician familiarity, hospital-based prescribing patterns.

The divalproex sodium market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growth of neuropsychiatric disorders, demand for cost-effective generics, improved patient adherence formulations, expanded mental health awareness, broader healthcare access. Major trends in the forecast period include steady demand for neurological disorder management, growing use in bipolar disorder treatment, expansion of extended-release formulations, increased focus on generic drug availability, rising monitoring of drug safety and dosage optimization.

The increasing prevalence of neurological disorders is expected to drive the growth of the divalproex sodium market in the coming years. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, leading to impaired function and symptoms such as seizures, muscle weakness, or cognitive difficulties. Rising life expectancy is a key factor contributing to the growing incidence of neurological disorders, as aging populations are more susceptible to conditions such as Alzheimer’s and Parkinson’s disease, which typically develop later in life. Divalproex sodium plays a critical role in the treatment of neurological disorders by stabilizing electrical activity in the brain, thereby preventing seizures and helping manage mood disturbances commonly associated with conditions such as epilepsy and bipolar disorder. For example, in October 2023, the World Federation of Neurology (WFN), a UK-based international nonprofit neurological organization, reported that more than 40% of the global population was living with a neurological condition, and the overall neurological disease burden is projected to nearly double by 2050. Therefore, the rising prevalence of neurological disorders is contributing to the growth of the divalproex sodium market.

Companies operating in the divalproex sodium market are increasingly focused on developing advanced formulations, such as delayed-release capsule therapies, to enhance patient convenience, reduce dosing frequency, and improve tolerability compared to immediate-release tablets. Delayed-release capsules are designed to release divalproex sodium at a controlled rate, helping maintain stable blood concentrations while minimizing peak-related side effects. For instance, in December 2024, Alembic Pharmaceuticals, an India-based generic drug manufacturer, received final approval from the US Food and Drug Administration (FDA) for its Divalproex Sodium Delayed Release Capsules USP, 125 mg. These capsules are therapeutically equivalent to the reference product, Depakote Sprinkle Capsules, and feature a sprinkle formulation that enables easier ingestion or administration, supporting better patient adherence and improved treatment outcomes.

In June 2024, Lotus Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired the Thailand business and commercial entity of Teva Pharmaceuticals for an undisclosed amount. Following the acquisition, Lotus will assume responsibility for the marketing and sales of Teva Pharma Thailand’s existing product portfolio, which will operate as a wholly owned subsidiary. This move allows Lotus to expand its presence in Thailand by adding respiratory and ophthalmic products to its portfolio and increasing its local workforce to approximately 100 employees, thereby strengthening its reach through hospital and pharmacy distribution channels. Teva Pharmaceuticals is an Israel-based manufacturer of divalproex sodium.

Major companies operating in the divalproex sodium market are AbbVie Inc., Sanofi S.A., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals Public Limited Company, Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Supernus Pharmaceuticals Inc., Strides Pharma Science Limited, Upsher-Smith Laboratories LLC, Ajanta Pharma Limited, Ishita Active Pharmaceutical Ingredients, Varahi International, Roaq Chemicals Private Limited, MSN Laboratories Private Limited.

North America was the largest region in the divalproex sodium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the divalproex sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the divalproex sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the divalproex sodium market by increasing costs of imported active pharmaceutical ingredients and excipients. North America and Europe are most affected due to reliance on global API supply chains, while emerging markets face pricing pressures. These tariffs increase production costs. However, they also encourage domestic API manufacturing and localized pharmaceutical production.

The divalproex sodium market research report is one of a series of new reports that provides divalproex sodium market statistics, including divalproex sodium industry global market size, regional shares, competitors with a divalproex sodium market share, detailed divalproex sodium market segments, market trends and opportunities, and any further data you may need to thrive in the divalproex sodium industry. This divalproex sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Divalproex sodium is a prescription drug used to treat certain neurological and psychiatric conditions. It is composed of a combination of sodium valproate and valproic acid, which function by increasing levels of gamma-aminobutyric acid (GABA), a brain chemical that helps reduce excessive nerve activity. By stabilizing electrical activity in the brain, this medication supports neurological and mental balance.

The main product types of divalproex sodium include tablets, capsules, extended-release tablets, and others. Tablets are solid oral dosage forms that contain active ingredients compressed into a specific shape for ease of administration. It can be administered via oral and intravenous routes and is used for epilepsy treatment, bipolar disorder management, migraine prevention, neuropsychiatric disorders, and other indications. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

The divalproex sodium market consists of sales of valproic acid oral solution, carbamazepine tablets, and lamotrigine tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.